Literature DB >> 810084

Experimental keratitis due to Pseudomonas aeruginosa: model for evaluation of antimicrobial drugs.

S D Davis, J W Chandler.   

Abstract

An improved method for experimental keratitis due to Pseudomonas aeruginosa is described. Essential features of the method are use of inbred guinea pigs, intracorneal injection of bacteria, subconjunctival injection of antibiotics, "blind" evaluation of results, and statistical analysis of data. Untreated ocular infections were most severe 5 to 7 days after infection. Sterilized bacterial suspensions caused no abnormalities on day 5. Tobramycin and polymyxin B were more active than gentamicin against two strains of Pseudomonas. This model is suitable for many types of quantitative studies on experimental keratitis.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 810084      PMCID： PMC429317          DOI： 10.1128/AAC.8.3.350

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Activity of gentamicin, tobramycin, polymyxin B, and colistimethate in mouse protection tests with Pseudomonas aeruginosa.

Authors:  S D Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

2.  A rapid chemical assay for gentamicin.

Authors:  D H Smith; B Van Otto; A L Smith
Journal:  N Engl J Med       Date:  1972-03-16       Impact factor: 91.245

Review 3.  Cornea and sclera.

Authors:  P R Laibson
Journal:  Arch Ophthalmol       Date:  1972-11

4.  Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media.

Authors:  L B Reller; F D Schoenknecht; M A Kenny; J C Sherris
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

5.  Experimental pseudomonas keratitis. Treatment with and evaluation of carbenicillin and gentamicin in combination.

Authors:  G Bohigian; M Okumoto; M Valenton
Journal:  Arch Ophthalmol       Date:  1971-10

6.  Treatment of Pseudomonas keratitis in rabbits.

Authors:  P C Hessburg; J P Truant; W P Penn
Journal:  Am J Ophthalmol       Date:  1966-01       Impact factor: 5.258

Review 7.  Management of pseudomonas keratitis.

Authors:  P C Hessburg
Journal:  Surv Ophthalmol       Date:  1969-07       Impact factor: 6.048

8.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

9.  Dissociation between results of in vitro and in vivo antibiotic susceptibility tests for some strains of Pseudomonas aeruginosa.

Authors:  S D Davis
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191
  9 in total
  6 in total

1.  Interleukin-8 production by human airway epithelial cells in response to Pseudomonas aeruginosa clinical isolates expressing type a or type b flagellins.

Authors:  Kathleen K Shanks; Wei Guang; K Chul Kim; Erik P Lillehoj
Journal:  Clin Vaccine Immunol       Date:  2010-06-30

Review 2.  Scope and limitations of experimental chemotherapy.

Authors:  O Zak
Journal:  Experientia       Date:  1980-04-15

Review 3.  Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use.

Authors:  R N Brogden; R M Pinder; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

4.  Pseudomonas aeruginosa: isolation from ocular tissues. Aeruginocin typing and its relationship to corneal pathogenicity in rabbits.

Authors:  V M Mahajan; T A Srikanth; L P Agarwal
Journal:  Int Ophthalmol       Date:  1982-02       Impact factor: 2.031

5.  Experimental Pseudomonas keratitis in guinea-pigs: therapy of moderately severe infections.

Authors:  S D Davis; L D Sarff; R A Hyndiuk
Journal:  Br J Ophthalmol       Date:  1979-06       Impact factor: 4.638

Review 6.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.